万邦德医药控股集团股份有限公司 简式权益变动报告书 上市公司名称：万邦德医药控股集团股份有限公司 信息披露义务人一：万邦德集团有限公司 住所及通讯地址：浙江省台州市温岭市城东街道楼山村百丈路西侧 信息披露义务人二：赵守明 住所及通讯地址：浙江省温岭市**** 信息披露义务人三：庄惠 住所及通讯地址：浙江省温岭市**** 信息披露义务人四：温岭惠邦投资咨询有限公司 住所及通讯地址：温岭市城东街道楼山村百丈路西侧 信息披露义务人五：温岭富邦投资咨询有限公司 住所及通讯地址：温岭市城东街道楼山村百丈路西侧 股份变动性质：股份减少（协议转让） 签署日期：二〇二五年七月十一日 上市地点：深圳证券交易所 股票简称：万邦德 股票代码：002082.SZ 信息披露义务人声明 一、本报告书系依据《中华人民共和国公司法》、《中华人民共和国证券法》、 《上市公司收购管理办法》、《公开发行证券的公司信息披露内容与格式准则第 15号——权益变动报告书》及相关法律、法规和规范性文件编写。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人章程或内部规则中的任何条款，或与之相冲突。 三、依据《中华人民共和 ...

万邦德：控股股东等拟协议转让公司9.8089%股份 智通财经7月11日电，万邦德(002082.SZ)公告称，公司控股股东万邦德集团、实际控制人赵守明、庄 惠、一致行动人温岭惠邦、温岭富邦拟通过协议转让方式，向温岭市万龙医药科技合伙企业转让其持有 的公司股票合计6000万股，占公司总股本的9.8089%。转让价格为6.88元/股，股份转让总价款合计为 4.128亿元。 ...

证券代码：002082 证券简称：万邦德 公告编号：2025-041 万邦德医药控股集团股份有限公司 股东名 称 是否为控股 股东或第一 大股东及其 一致行动人 本次解除质 押股份数量 (股) 占其所 持股份 比例（%） 占公司总 股本比例 （%） 质押起 始日 质押解 除日 质权人 赵守明 是 150,000 0.30 0.02 2023 年 7 月 7 日 2025 年 7 月 7 日 浙股（杭州） 企业管理有限 公司 赵守明 是 10,000,000 20.13 1.63 2023 年 9 月 11 日 2025 年 7 月 7 日 浙股（杭州） 企业管理有限 公司 庄惠 是 9,850,000 34.89 1.61 2023 年 7 月 7 日 2025 年 7 月 7 日 浙股（杭州） 企业管理有限 公司 一、股东股份解除质押基本情况 三、股东股份累计质押情况 | | | | | | | | 已质押 | | 未质押 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | 占其 | 占公 | ...

Group 1: Company Performance - Wanwei High-tech expects a net profit of 235 million to 265 million yuan for the first half of 2025, representing a year-on-year increase of 81.34% to 104.48% [1] - Jin Guan Electric has won bids for projects from Southern Power Grid and Guangxi Power Grid, with a total bid amount of approximately 42.81 million yuan, accounting for 5.76% of the company's 2024 revenue [2] - Ankai Bus reported a June vehicle sales increase of 37.88% year-on-year, with a total production of 814 vehicles, a 52.23% increase [4] - Daqin Railway's June cargo transport volume increased by 5.29% year-on-year, totaling 32.42 million tons [5] - Xianggang Technology anticipates a net profit of 75 million to 85 million yuan for the first half of 2025, a year-on-year increase of 410% to 478% [9] - Longxin General expects a net profit of 1.005 billion to 1.12 billion yuan for the first half of 2025, a year-on-year increase of 70.52% to 90.03% [10] - Le Xin Technology forecasts a net profit of 250 million to 270 million yuan for the first half of 2025, a year-on-year increase of 65% to 78% [11] - I-Le Furniture expects a net profit of 80 million to 99 million yuan for the first half of 2025, a year-on-year increase of 76.08% to 117.90% [13] - Shennong Group sold 219,000 pigs in June, generating sales revenue of 385 million yuan [14] - Guohuo Airlines anticipates a net profit of 1.187 billion to 1.267 billion yuan for the first half of 2025, a year-on-year increase of 78.13% to 90.14% [45] Group 2: Industry Developments - The electric power equipment industry is seeing increased project bids, as evidenced by Jin Guan Electric's recent contracts [2] - The automotive industry is experiencing growth, with Ankai Bus reporting significant increases in both production and sales [4] - The railway transportation sector is showing resilience with Daqin Railway's cargo transport volume growth [5] - The pharmaceutical industry is advancing with clinical trial approvals, such as Wanbang's WP107 oral solution for treating myasthenia gravis [6] - The packaging and printing industry is witnessing substantial profit growth, as indicated by Xianggang Technology's performance forecast [9] - The agricultural sector, particularly in pig farming, is maintaining steady sales figures, as shown by Shennong Group's sales data [14]

一、 药物基本情况 药品名称：WP107 口服溶液 受理号：CXHL2500409 适应症：重症肌无力 申请事项：临床试验申请 申请人：万邦德制药集团有限公司 审批结论：同意本品开展"用于重症肌无力的治疗"适应症的临床试验。 证券代码：002082 证券简称：万邦德 公告编号：2025-040 万邦德医药控股集团股份有限公司 关于子公司药品获得《药物临床试验批准通知书》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 万邦德医药控股集团股份有限公司（以下简称"公司"）全资子公司万邦德 制药集团有限公司于近日收到国家药品监督管理局（以下简称"国家药监局"） 核准签发的《药物临床试验批准通知书》，公司自主研发的 WP107 口服溶液用于 治疗"重症肌无力"的临床试验申请获得批准。现将相关情况公告如下： 本次药物临床试验获得批准，进一步加快公司在研产品的进度，短期内对公 司经营业绩不会产生重大影响，公司将按照相关规定和要求继续开展临床试验。 药品研发具有高投入、高风险、长周期等特点，临床试验进度及结果、未来 产品市场竞争形势均存在不确定性，会受到不可预测因素的 ...

万邦德（002082）公告，全资子公司万邦德制药集团有限公司收到国家药监局核准签发的《药物临床试 验批准通知书》，公司自主研发的WP107口服溶液用于治疗"重症肌无力"的临床试验申请获得批准。此 次批准旨在评估WP107口服溶液在全身型重症肌无力受试者中的药代动力学和安全性。公司此前于2023 年12月获得美国FDA授予的石杉碱甲治疗重症肌无力的孤儿药认定，于2025年1月WP107口服溶液用于 治疗"全身型重症肌无力"获得美国FDA新药临床试验许可。 ...

Group 1 - Taotao Automotive expects a net profit of 310 million to 360 million yuan for the first half of 2025, representing a year-on-year increase of 70.34% to 97.81% [1] - The company specializes in the research, production, and sales of all-terrain vehicles, electric golf carts, electric scooters, electric balance bikes, electric bicycles, and their accessories [1] - China Communications Construction Company plans to repurchase shares worth between 500 million to 1 billion yuan, with a maximum repurchase price of 13.58 yuan per share [1][2] Group 2 - Annoqi's subsidiary received a government subsidy of 1.65 million yuan, accounting for 34.77% of the company's latest audited net profit [2] - Annoqi focuses on the research, production, and sales of mid-to-high-end differentiated dyes [3] - Minfeng Special Paper announced the complete shutdown of its Nanhu plant, as its Haiyan plant is now capable of handling the production capacity [4] Group 3 - Aoto Electronics received a trademark registration certificate from Saudi Arabia, covering various electronic products [5] - Landi Group plans to acquire up to 20.1667% of the shares of Jujia Technology for a total price not exceeding 121 million yuan [6][7] - Lifan Pharmaceutical's Danpi phenol raw material drug has been approved for market launch, utilizing a new process that enhances efficiency and meets market demand [8] Group 4 - Shanghai Construction received a total of 548 million yuan in government subsidies, which accounts for 22.79% of the company's latest audited net profit [8] - Wanbangde's subsidiary received ethical approval for a key clinical trial of a new drug for Alzheimer's disease [8] - Prolo Pharmaceutical's subsidiary received approval for the market launch of a new raw material drug for liver cancer treatment [9] Group 5 - Chenguang New Materials received a government subsidy of 26 million yuan, representing 62.86% of the company's latest audited net profit [10] - Sanyou Medical's subsidiary received a government subsidy of 331,000 yuan, accounting for 28.86% of the company's latest audited net profit [11] - Weichai Heavy Machinery expects a net profit of 132 million to 151 million yuan for the first half of 2025, reflecting a year-on-year increase of 40% to 60% [12] Group 6 - Guanhao Biological announced the termination of its application for a specific stock issuance [13] - China Film plans to use up to 1.5 billion yuan of idle funds for cash management [14] - Aotai Biological intends to use up to 480 million yuan of idle raised funds for cash management [15] Group 7 - Helin Micro-Nano is planning to issue overseas shares and list on the Hong Kong Stock Exchange [17] - Jinpan Technology's vice president resigned due to personal health reasons [18] - Tongyi Zhong's chairman and general manager plan to reduce their shareholdings in the company [19] Group 8 - Naipu Mining signed an overseas contract worth 18.85 million USD [21] - Zhengye Technology completed an asset sale transaction worth 178 million yuan [23] - Lianxin Equipment won a bid for a project worth 157 million yuan from BOE [24] Group 9 - Smart Control plans to apply for a comprehensive credit line of up to 260 million yuan from banks [25] - Keyuan Pharmaceutical's application for issuing shares to purchase assets has been accepted by the Shenzhen Stock Exchange [27] - Meige Intelligent's H-share listing application materials have been received by the China Securities Regulatory Commission [29] Group 10 - Siwei Tuxin's subsidiary submitted an H-share listing application [32] - Metro Design's application for issuing shares to purchase assets has been accepted by the Shenzhen Stock Exchange [32] - Aeston submitted an application for H-share listing [34] Group 11 - Jiu Ri New Materials' shareholders plan to reduce their holdings by a total of 98,900 shares [34] - Yihua Tong's shareholder plans to reduce their holdings by up to 700,000 shares [35] - Xishanghai plans to distribute a cash dividend of 0.08 yuan per share [36] Group 12 - Zhejiang Natural plans to distribute a cash dividend of 1.97 yuan for every 10 shares [37] - Kouzi Jiao plans to distribute a cash dividend of 1.30 yuan per share [38] - Huitong Group plans to distribute a cash dividend of 0.023 yuan per share [40] Group 13 - Tongyong Co. plans to reduce its holdings by up to 0.31% of the company's shares [41] - China Shenhua plans to distribute a cash dividend of 2.26 yuan for every 10 shares [43] - Huangting International's executive director resigned due to personal reasons [45] Group 14 - Jinkai New Energy plans to distribute a cash dividend of 1 yuan for every 10 shares [46] - Heimu Dan plans to distribute a cash dividend of 0.041 yuan per share [47] - Feiyada plans to acquire all or part of the controlling stake in Chang Kong Gear [48]

证券代码：002082 证券简称：万邦德 公告编号：2025-039 万邦德医药控股集团股份有限公司 关于控股股东及实际控制人股份解除质押及再质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 万邦德医药控股集团股份有限公司（以下简称"公司"）于近日收到控股股 东万邦德集团有限公司（以下简称"万邦德集团"）及实际控制人赵守明先生的 通知，获悉其所持有公司的部分股份办理了解除质押及再质押手续，具体事项如 下： | 股东名 | 是否为控股 股东或第一 | 本次解除质 | 占其所 | 占公司总 | 质押起 | 质押解 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 称 | 大股东及其 | 押股份数量 | 持股份 | 股本比例 | 始日 | 除日 | 质权人 | | | 一致行动人 | (股) | 比例（%） | （%） | | | | | 万邦德 | 是 | 106,460,000 | 55.04 | 17.40 | 2022 年 5 | 2025 年 6 | | | 集团 | | | | | ...

证券代码：002082 证券简称：万邦德 公告编号：2025-038 万邦德医药控股集团股份有限公司 关于子公司石杉碱甲控释片获得伦理批件的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 万邦德医药控股集团股份有限公司（以下简称"公司"）全资子公司万邦 德制药集团有限公司的 2.2 类新药石杉碱甲控释片治疗轻中度阿尔茨海默病型 痴呆的关键注册临床试验近日获得了组长单位首都医科大学宣武医院伦理审查 委员会的审查批件，批准项目开展。现将相关情况公告如下： 一、药品及获得伦理批件基本情况 名称：石杉碱甲控释片 英文名称：Huperzine A Controlled-Release Tablets 剂型：片剂 规格：0.2mg 注册分类：2.2 类新药 适应症：轻中度阿尔茨海默病型痴呆 临床研究阶段：Ⅱ/Ⅲ期 临床研究组长单位：首都医科大学宣武医院 伦理审查委员会审查意见：同意临床试验 二、药品临床试验进展情况 石杉碱甲控释片是公司自主研发的用于治疗轻中度阿尔茨海默病型痴呆的 2.2 类新药，采用双相控释技术，平缓药物释放峰谷曲线，并延长药物体内释放 时间，实现 ...

Group 1 - Company GuoDeWei plans to repurchase shares with a total investment of between 100 million to 150 million yuan, with a maximum repurchase price of 53 yuan per share, expecting to buy back between 1.89 million to 2.83 million shares, accounting for 0.78% to 1.17% of total share capital [1] - Company Shuangliang Energy has won a bid for the Gansu Energy Chemical Qinyang 2×660MW coal power project, with a total bid amount of 237 million yuan, representing 1.82% of the company's projected revenue for 2024 [1] - Company China Pacific Insurance reported a total premium income of 227.17 billion yuan from its two subsidiaries in the first five months, with a year-on-year growth of 10.2% for its life insurance subsidiary and 0.5% for its property insurance subsidiary [1][2] Group 2 - Company LuKang Pharmaceutical has received a drug registration certificate for injectable Cefoperazone Sodium, a third-generation cephalosporin with broad-spectrum antibacterial properties [3] - Company 吉祥航空 reported a 4.97% year-on-year increase in passenger turnover in May, with a seat occupancy rate of 86.14%, up 3.70% year-on-year [4][5] - Company DuRui Pharmaceutical's subsidiary has also received a drug registration certificate for injectable Cefoperazone Sodium [6] Group 3 - Company KeLan Software announced that part of the shares held by its controlling shareholder will be auctioned, involving 5.09 million shares, accounting for 1.07% of the total share capital [7] - Company HuaCan Optoelectronics received a government subsidy of 87.84 million yuan, which is expected to positively impact the company's pre-tax profit for 2025 [8] - Company JinZhi Technology has won a bid for projects from the State Grid and China Resources New Energy, with a total bid amount of 84.41 million yuan [9] Group 4 - Company Vision China completed a capital increase for its subsidiary, raising 100 million yuan to accelerate its layout in the AI field [11] - Company Youa Co. received a profit distribution of 96.03 million yuan from its investment in Changsha Bank [13] - Company WanBangde's subsidiary obtained a patent for a deuterated compound, enhancing the chemical stability and reducing toxicity [16] Group 5 - Company DongCheng Pharmaceutical completed the enrollment of all 488 participants in the Phase III clinical trial for Fluorine-18 PSMA peptide injection, aimed at prostate cancer diagnosis [17] - Company China Merchants Expressway announced that its first phase of medium-term notes for 2024 will pay interest on July 2, 2025, with a total issuance of 2.5 billion yuan and an interest rate of 2.35% [18] - Company JinPu Titanium's subsidiary has temporarily suspended production for maintenance due to falling product prices and high production costs [20] Group 6 - Company BeiLu Pharmaceutical received a marketing authorization for Iodinated Contrast Injection in Hungary, marking another approval in the EU [22] - Company LiXing Co. obtained an overseas investment certificate for its wholly-owned subsidiary in Singapore, with a total investment of 2.16 million yuan [24] - Company LangKun Technology won a garbage collection service project with a bid amount of 21.57 million yuan [26] Group 7 - Company KeRui International plans to transfer 55% of its subsidiary Tianjin ZhiRui's equity for 41.96 million yuan [28] - Company Nanjing JuLong intends to invest 130 million yuan to build a production project for special materials with an annual output of 40,000 tons [30] - Company NanShan Intelligent plans to use up to 50 million yuan of idle funds for cash management in safe and liquid financial products [32] Group 8 - Company GuangLian Aviation completed the business change registration for its subsidiary, involving the introduction of strategic investors [34] - Company XiaoFang Pharmaceutical signed a cooperation agreement to develop a new drug for hair loss treatment [36] - Company GuiZhou SanLi plans to sign a 150 million yuan technology transfer and development contract with Guangdong Pharmaceutical University [38] Group 9 - Company ST SiLong's subsidiary received a drug registration certificate for Famotidine injection, used for treating upper gastrointestinal bleeding [52] - Company ZhongKe Information's executive plans to reduce holdings of up to 180,000 shares, accounting for 0.06% of total share capital [53] - Company KeLun Pharmaceutical's injectable Cefoperazone Sodium/Chloride Sodium injection received drug registration approval [54] Group 10 - Company LuXin Investment plans to transfer 10.06% of its stake in LuXin HuiJin for 203 million yuan, aiming to focus on its main business [56] - Company Western Gold plans to acquire 100% of Xinjiang MeiSheng for 1.655 billion yuan [58] - Company JinTou City Development intends to swap assets worth 5.862 billion yuan, changing its main business to urban centralized heating [60]